Effect of Tenofovir and Entecavir on Patients With Compensatory Hepatitis B Cirrhosis
Objective To explore the effect of tenofovir and entecavir in patients with liver cirrhosis in compensatory stage.Methods From May 2021 to May 2022,a total of 70 patients with compensated hepatitis B cirrhosis who were admitted to Zibo Hospital of Infectious Diseases were selected and divided into the control group and the observation group by random number table,with 35 cases in each group.The control group was treated with entecavir,while the observation group was treated with tenofovir.The clinical efficacy,liver function,liver fibrosis index,negative rate of hepatitis B virus deoxyribonucleic acid(HBV-DNA),platelet and aspartate aminotransferase,platelet ratio index(APRI),organ morphological changes and complications were compared between the two groups.Results The total effective rate of the observation group was 97.14%,which higher than that of the control group(80.00%)(P<0.05).The scores of ASpartate transaminase,alanine transaminase and Child-Pugh in 2 groups were lower after treatment than before treatment.After treatment,the scores of aspartate transaminase,alanine transaminase and Child-Pugh in observation group were lower than those in control group,with statistical significance(P<0.05).Before treatment,there was no significant difference in serum levels of laminin,hyaluronic acid and type Ⅲ procollagen peptide between 2 groups(P>0.05).Serum laminin,hyaluronic acid and typeⅢ procollagen peptide were lower in 2 groups after treatment than before treatment.After treatment,the serum laminin,hyaluronic acid and type Ⅲ procollagen peptide in observation group were lower than those in control group,and the difference was statistically significant(P<0.05).After treatment,the platelet counts were higher,aspartate aminotransferase and platelet ratio index were lower in 2 groups than those before treatment.After treatment,the platelet count,aspartate aminotransferase and platelet ratio index in observation group were higher than those in control group,with statistical significance(P<0.05).The internal diameter of hepatic portal vein was lower and the thickness of spleen was lower in 2 groups after treatment and before treatment.After treatment,the intrahepatic portal vein diameter and spleen thickness in the observation group were lower than those in the control group,with statistical significance(P<0.05).The negative conversion rate of HBV-DVA was higher in both groups after 180 days and 90 days of treatment.After treatment,the negative conversion rate of HBV-DVA in observation group was higher than that in control group,and the difference was statistically significant(P<0.05).Conclusion Entecavir combined with tenofovir in the treatment of compensatory hepatitis B cirrhosis can obtain outstanding therapeutic effect,can effectively improve the liver function index of patients,and can effectively block the hepatitis B viral load,which is worthy of clinical promotion.
compensation periodhepatitis B cirrhosistenofovirentecavirliver function indexhepatitis B virus
NETL
NSTL
万方数据
